From Yahoo Finance: 2025-04-11 12:10:00

Truist predicts Summit Therapeutics’ HARMONi-2 study could exceed expectations, potentially showing statistical significance. The firm’s biostatistics expert consultation indicates a “home-run scenario” that could significantly boost Summit’s shares. Truist maintains a Buy rating and sets a $35 price target on the stock. The study’s results are highly anticipated in the biotech community.

Read more: Expert says Summit’s HARMONi-2 study could beat expectations, says Truist